Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Indiva Reports Fiscal Year 2023 Results Including Record Positive EBITDA and Income (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Albert Labs International Corp C.ABRT

Alternate Symbol(s):  ALBLF

Albert Labs International Corp. is a Canada-based pharmaceutical drug development company. The Company is focused on active compounds in the treatment of mental health and providing rapid access to effective prescription medicines for people suffering from mental health disorders. The Company operates primarily in one business segment: research and development of drugs to ensure accelerated access to safe and effective psychedelic-assisted therapy for patients with urgent, unmet needs. The Company also focuses on developing solutions through an approved, fast track clinical pathway focusing on Real World Evidence (RWE). The Company's first drug target, KRN-101, is a potential solution for cancer-related anxiety. KRN-101 is derived from natural psilocybin mycelium. Through collaborations with research institutions, hospital centers and government agencies, the Company uses existing clinical infrastructure to deliver and improve patient access to its treatment.


CSE:ABRT - Post by User

Albert Labs International Corp
Bullboard Posts
User Avatar Image
(0)
•••
Post by aiminvestoron Feb 17, 2012 7:42pm
221 Views
Post# 19552670

Oh dear!

Oh dear!

ME Resource Corp
Symbol C : MEC
Shares Issued 19,583,372
Recent Sedar Documents

No BIDS AT ALL!

anyone holding cannot sell at any price, commiserations to holders.

ME Resource confirms Pakistani deal falls through

2012-02-16 17:37 ET - News Release

Mr. Navchand Jagpal reports

ME Resource Corp. had to cancel the transaction to acquire a 70-per-cent interest in two exploration licences in the Chagi mineral belt in Balochistan province, northwest Pakistan, as disclosed in a press release dated Jan. 21, 2012. The company was unable to raise the funds necessary to acquire the exploration licences and therefore will not be able to proceed with the share distribution to the vendors.

We seek Safe Harbor.

Bullboard Posts
Dealroom for high-potential pre-IPO opportunities